Literature DB >> 15728913

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Deborah L Higgins1, Ray Chang, Dmitri V Debabov, Joey Leung, Terry Wu, Kevin M Krause, Erik Sandvik, Jeffrey M Hubbard, Koné Kaniga, Donald E Schmidt, Qiufeng Gao, Robert T Cass, Dane E Karr, Bret M Benton, Patrick P Humphrey.   

Abstract

The emergence and spread of multidrug-resistant gram-positive bacteria represent a serious clinical problem. Telavancin is a novel lipoglycopeptide antibiotic that possesses rapid in vitro bactericidal activity against a broad spectrum of clinically relevant gram-positive pathogens. Here we demonstrate that telavancin's antibacterial activity derives from at least two mechanisms. As observed with vancomycin, telavancin inhibited late-stage peptidoglycan biosynthesis in a substrate-dependent fashion and bound the cell wall, as it did the lipid II surrogate tripeptide N,N'-diacetyl-L-lysinyl-D-alanyl-D-alanine, with high affinity. Telavancin also perturbed bacterial cell membrane potential and permeability. In methicillin-resistant Staphylococcus aureus, telavancin caused rapid, concentration-dependent depolarization of the plasma membrane, increases in permeability, and leakage of cellular ATP and K(+). The timing of these changes correlated with rapid , concentration-dependent loss of bacterial viability, suggesting that the early bactericidal activity of telavancin results from dissipation of cell membrane potential and an increase in membrane permeability. Binding and cell fractionation studies provided direct evidence for an interaction of telavancin with the bacterial cell membrane; stronger binding interactions were observed with the bacterial cell wall and cell membrane relative to vancomycin. We suggest that this multifunctional mechanism of action confers advantageous antibacterial properties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728913      PMCID: PMC549257          DOI: 10.1128/AAC.49.3.1127-1134.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

1.  Chlorobiphenyl-desleucyl-vancomycin inhibits the transglycosylation process required for peptidoglycan synthesis in bacteria in the absence of dipeptide binding.

Authors:  R C Goldman; E R Baizman; C B Longley; A A Branstrom
Journal:  FEMS Microbiol Lett       Date:  2000-02-15       Impact factor: 2.742

2.  In situ assay for identifying inhibitors of bacterial transglycosylase.

Authors:  A A Branstrom; S Midha; R C Goldman
Journal:  FEMS Microbiol Lett       Date:  2000-10-15       Impact factor: 2.742

3.  Fluorescent method for monitoring cheese starter permeabilization and lysis.

Authors:  C J Bunthof; S van Schalkwijk; W Meijer; T Abee; J Hugenholtz
Journal:  Appl Environ Microbiol       Date:  2001-09       Impact factor: 4.792

4.  Binding of glycopeptide antibiotics to a model of a vancomycin-resistant bacterium.

Authors:  M A Cooper; D H Williams
Journal:  Chem Biol       Date:  1999-12

5.  Antibacterial activity of synthetic analogues based on the disaccharide structure of moenomycin, an inhibitor of bacterial transglycosylase.

Authors:  E R Baizman; A A Branstrom; C B Longley; N Allanson; M J Sofia; D Gange; R C Goldman
Journal:  Microbiology       Date:  2000-12       Impact factor: 2.777

6.  Use of affinity capillary electrophoresis to determine kinetic and equilibrium constants for binding of arylsulfonamides to bovine carbonic anhydrase.

Authors:  L Z Avila; Y H Chu; E C Blossey; G M Whitesides
Journal:  J Med Chem       Date:  1993-01-08       Impact factor: 7.446

Review 7.  Structure, biochemistry and mechanism of action of glycopeptide antibiotics.

Authors:  P E Reynolds
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-11       Impact factor: 3.267

8.  Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic.

Authors:  E Breukink; I Wiedemann; C van Kraaij; O P Kuipers; H G Sahl; B de Kruijff
Journal:  Science       Date:  1999-12-17       Impact factor: 47.728

9.  Synthesis and antibacterial evaluation of N-alkyl vancomycins.

Authors:  R Nagarajan; A A Schabel; J L Occolowitz; F T Counter; J L Ott; A M Felty-Duckworth
Journal:  J Antibiot (Tokyo)       Date:  1989-01       Impact factor: 2.649

10.  One-step purification procedure for UDP-N-acetylmuramyl-peptide murein precursors from Bacillus cereus.

Authors:  U Kohlrausch; J V Höltje
Journal:  FEMS Microbiol Lett       Date:  1991-03-01       Impact factor: 2.742

View more
  131 in total

1.  Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.

Authors:  Rodrigo E Mendes; Helio S Sader; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

2.  Native valve endocarditis caused by Corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?

Authors:  Truc T Tran; Siraya Jaijakul; Cole T Lewis; Lorena Diaz; Diana Panesso; Heidi B Kaplan; Barbara E Murray; Audrey Wanger; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

3.  Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.

Authors:  Gengrong Lin; Glenn A Pankuch; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

4.  Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance.

Authors:  Richard Pushkin; Steven L Barriere; Whedy Wang; G Ralph Corey; Martin E Stryjewski
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

Review 5.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

6.  Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.

Authors:  Adam Belley; Geoffrey A McKay; Francis F Arhin; Ingrid Sarmiento; Sylvain Beaulieu; Ibthihal Fadhil; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

7.  N-thiolated beta-lactams: Studies on the mode of action and identification of a primary cellular target in Staphylococcus aureus.

Authors:  Kevin D Revell; Bart Heldreth; Timothy E Long; Seyoung Jang; Edward Turos
Journal:  Bioorg Med Chem       Date:  2006-12-20       Impact factor: 3.641

8.  Anti-methicillin Resistant Staphylococcus aureus Compound Isolation from Halophilic Bacillus amyloliquefaciens MHB1 and Determination of Its Mode of Action Using Electron Microscope and Flow Cytometry Analysis.

Authors:  Venkadapathi Jeyanthi; Palaniyandi Velusamy
Journal:  Indian J Microbiol       Date:  2016-01-30       Impact factor: 2.461

9.  In Vitro Synergy of Telavancin and Rifampin Against Enterococcus faecium Resistant to Both Linezolid and Vancomycin.

Authors:  George A Pankey; Deborah S Ashcraft
Journal:  Ochsner J       Date:  2013

Review 10.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.